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PGE2 prostaglandins E2 
AA arachidonic acid 
PLA2 phospholipase A2 
COX cyclooxygenase 
PGH2 prostaglandin H2 
PGD2 prostaglandin D2 
PGI2 prostaglandin I2 
TXA2 thromboxane A2 
PGF2α prostaglandin F2α 
GPCR G-protein coupled receptors
PPAR peroxisome proliferator activated receptors




MAPK mitogen-activated protein kinases
PI3K phosphoinositide 3-kinases
NFAT nuclear factor of activated T cells
c-Src tyrosine-protein kinase Src
NF κB nuclear factor-kappa B
AC adenylate cyclase
cAMP cyclic adenosine monophosphate
PKA protein kinase A
CREB cAMP response element binding protein
ERKs regulated kinases
EGR-1 growth response factor-1
EVTs extravillous trophoblasts
FGF fibroblast growth factor
VEGF vascular endothelial growth factor
NK natural kill
ITG integrins
FAK focal adhesion kinase
EGFR epidermal growth factor receptor
HCC hepatocellular carcinoma
EMT epithelial mesenchymal transformation
MMP matrix metalloproteinases
GSK-3 glycogen synthase kinase 3
RAC1 ras related C3 botulinum toxin substrate 1
CDC42 control protein 42 homolog
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ECM extracellular matrix 
TIMPs tissue inhibitors of metalloproteinase 
PAI-1 plasminogen activator inhibitor-1 
DC dendritic cell 
VEGF vascular endothelial growth factor 
bFGF basic fibroblast growth factor 
TGFβ transforming growth factor-β 
PDGF platelet derived growth factor 
TNFα tumor necrosis factor α 
IL interleukin 
LIF leukemia inhibitory factor  
MDSC myeloid derived suppressor cells 
IFN interferons 
CCL chemokines chemokine ligand  
XCL chemokine c motif ligand 
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Prostaglandin E2 (PGE2) is the most biologically active prostaglandin and exists at 
different concentrations in nearly all cell types, regulating various physiological and 
pathological processes in the reproductive, cardiovascular, musculoskeletal, 
endocrine, nervous and immune systems [1-4]. Therefore, it also influences the 
disease severity in several conditions such as infertility, gynecologic cancers, 
endometriosis, polycystic ovary syndrome and pre-eclampsia in female reproductive 
system [5-8]. PGE2 contributes to the regulation of cellular functions, immune 
response and cell-cell interaction [9]. This thesis summarizes our current 
understanding of PGE2 biosynthesis and the role played by the cyclooxygenase 2 
(COX-2)-prostaglandin E2(PGE2)-prostaglandin E2 receptors (EPs) signaling pathway 
in mediating both the similar and different functions it exerts within the placenta and 
cancer cells through cell proliferation, adhesion, migration, invasion, secretion of matrix 
metalloproteinases, angiogenesis and immunosuppression. We assume that these 
similarities and differences can yield new insights or improve the treatment of placental 
diseases and cancers. 
3.1 PGE2 synthesis and signaling cascade 
Prostaglandin (PG) synthesis can be divided into three steps: Firstly, membrane 
phospholipid from via the enzyme phospholipase A2 (PLA2) is the source of 
arachidonic acid (AA). Secondly, cyclooxygenase (COX) enzymes oxidize the free AA 
to form prostaglandin endoperoxides. As the rate-limiting enzymes, COX-1 or COX-2 
convert the prostaglandin endoperoxides specifically prostaglandin G2 into bioactive 
prostaglandin H2 (PGH2), an unsteady transitional compound which is speedily 
converted into other prostanoids by specific terminal PG synthases. Thirdly, depending 
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on particular enzymes (PGDS, PGES, PGFS and PGIS). When modified, PGH2 
produces five different metabolites known as prostaglandin F2α (PGF2α), 
prostaglandin D2 (PGD2), prostaglandin I2 (PGI2), thromboxane A2 (TXA2), and PGE2. 
Aspirin and indomethacin, which are non-steroidal anti-inflammatory drugs, perform 
their anti-inflammatory functions by suppressing COX enzymes, thus inhibiting the 
production of PGs. All of these prostaglandins (PGD2, PGE2, PGI2 PGF2α, and TXA2) 
modulate a series of cellular functions by binding to cell surface G-protein coupled 
receptors (GPCR) to intercede their impacts, also known as the EP, DP, FP, IP and 
TP receptors [10]. PGE2 is the most abundant PG observed in tissues. It exerts 
versatile physiological and pathological actions in autocrine and paracrine glands. 
PGE2 receptors consist of 4 GPCR, called EP1, EP2, EP3 and EP4, each of which 
differs in terms of intracellular signaling transduction properties, and applies assorted 
functions throughout the body [11,12]. PGE2 can also function as a ligand for three 
nuclear receptors, peroxisome proliferator activated receptors (PPARα, PPARβ/δ, 
PPAR γ) and therefore activate nuclear transcription factors [13].  
EP1 is coupled to the G-protein subunit Gq (Gq) and induces the Ca2+ protein 
channel leading to the increasing of intracellular Ca2+ and activation of protein kinase 
C (PKC) by phospholipase C (PLC) that elevates the second messenger inositol 
trisphosphate (IP3) and diacylglycerol (DAG) [14]. PKC stimulates the mitogen-
activated protein kinases (MAPK) and phosphoinositide 3-kinases (PI3K) flagging 
pathways, and furthermore actuates the record factors called atomic factor of initiated 
T-cells (NFAT), proto-oncogene tyrosine-protein kinase Src (c-Src), and atomic factor-
kappa B (NF-κB) [15-17]. [15-17]. EP2 and EP4 are coupled to the G-protein subunit 
(Gs) and subsequently invigorate adenylate cyclase (AC), prompting raised cyclic 
adenosine monophosphate (cAMP) creation that initiates protein kinase A (PKA) just 
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as the cAMP response element (CRE)-binding protein (CREB) pathway [18]. Moreover, 
EP2 and EP4 have been shown to activate PI3K through the β-arrestin signaling 
pathway [19]. Subsequently, PI3K activation promotes extracellular signal regulated 
kinases (ERKs) signaling and induces early growth response factor-1 (EGR-1) [20]. 
ERG-1 has been shown to increase COX-2 expression levels and activate nuclear β-
catenin [21]. EP3 is coupled with Gi and inhibits AC, thereby decreases cAMP via Gi, 
elicits Ca2+ mobilization and suppresses PKA and PI3K activation. Surprisingly, EP3 
could also be coupled to Gas, then induce NF-κB and CREB [12]. Figure 1. 
Figure 1: An overview of PGE2 biosynthesis and signaling cascade. 
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The membrane of phospholipids releases arachidonic acid (AA) by phospholipase A2 (PLA2). 
PGE2 is synthesized from arachidonic acid by cyclooxygenase (COX) enzymes and PGES via 
the unstable intermediate forms PGH2, which can be modified to TXA2, PGD2, PGF2a and 
PGI2. NSAIDs exerts their anti-inflammatory actions by the inhibition of COX activity. PGE2 
performs signaling in both paracrine and autocrine manners through four different types of EP-
GPCRs, namely EP1, EP2, EP3, and EP4. EP1 couples with Gq and activate PLC which then 
increases IP3 and DAG with the opening of Ca2+ channels leading to the increase of intracellular 
Ca2+ and activation of PKC that leads to the activation of nuclear factor of activated T-cells 
(NFAT), Proto-oncogene tyrosine-protein kinase Src (c-Src), nuclear factor-kappa (NFκB) and 
the MAPK pathways. EP2/EP4 couple with Gs and activates adenylate cyclase (AC) leading 
to higher levels of cyclic adenosine monophosphate (cAMP) that activates protein kinase A 
(PKA) as well as the cAMP response element-binding protein (CREB). EP3 couples with Gi to 
decrease cAMP levels. Multiple signaling pathways are involved, including EP3-PKA-pERK, 
EP3-PI3K, EP3-CREB and EP3-NFκB. 
3.2 Similar characteristics in placenta and tumor cells 
The placenta is a temporary organ that develops sustained apposition and 
communications between maternal and fetal tissues for gas and nutrient exchange, 
which shares significant similarities with cancer. Firstly, both the placenta and tumors 
have a lot of effectively partitioning cells, to be specific trophoblasts particularly 
cytotrophoblast cells in the placenta and cancer cells in tumors.  
Secondly, placentation is a complex multistage process and can be divided into 
three distinct phases. The first phase, blastocyst apposition and attachment, is 
mediated by hormones secreted from the luminal and glandular epithelial cells. The 
second phase is regulated by endogenous steroidal hormones inducing changes in the 
epithelial, stromal cells and maternal vasculature by emitting embryonic signals. The 
final step is associated with trophoblast invasion and endometrial remodeling [22]. 
Cancer is also a multistage disease [23]. Tumorigenesis begins with a cluster of 
genetic mutations leading to abnormal cell proliferation, contributing to a monoclonal 
population outgrowth. Next, these neoplastic cells acquire the ability to resist apoptotic 
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signals and display increased angiogenesis. Finally, the adhesion of cancer cells 
breaks down the basement membrane, leading to cancer cells invasion and metastasis 
to other tissues and organs.   
Thirdly, cytotrophoblast cells migrate through the anchoring villi with the capacity of 
proliferation, invasion, the ability to escape any attack from the maternal immune 
system, and survive under extreme hypoxic conditions and lack of blood supply, 
making them a model for comparison with tumors [24]. The invasion of these 
extravillous trophoblasts (EVTs) into the maternal decidua marks an essential step in 
embryo implantation and establishing a successful pregnancy. Broad vascularization 
and angiogenesis are standard highlights shared by malignancy cells and trophoblasts 
found at the maternal-fetal interface [25]. Both require blood provided by means of new 
vessels to develop. Cytokines, for example, fibroblast development factor (FGF) and 
vascular endothelial growth factor (VEGF) are essential parts that assume a pivotal job 
in tumor expansion, spiral artery remodeling, and angiogenesis [26].  
Lastly, the maternal-fetal interface and the tumor microenvironment show 
amazingly comparable features. These comparable features consist of the similarities 
in immune cells involved including T cells, B cells, macrophages, natural killer (NK) 
cells, dendritic cells, and neutrophils. These infiltrating cells are more likely polarized 
to the immunosuppressive microenvironment. The placenta and tumor cells consist of 
similar cell types and express numerous common cytokines and chemokines. 
3.3 Function of the PGE2 pathway in adhesion and proliferation 
The focal adhesion pathway is a critical molecular pathway affected by suboptimal 
culture conditions during embryonic development and tumor progression [27,28].  
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PGE2 promotes embryo adhesion during the implantation window both in the 
natural cycle and in vitro fertilization [29]. PGE2 phosphorylates MAPK1/MAPK3 
through EP2 receptors and boosts the adhesive capacity of trophoblasts by 
upregulating adhesion proteins such as focal adhesion kinase and intercellular 
adhesion molecule-1 [30]. Huang et al. reported that PGE2 lead to an increase in the 
expression levels of integrins (ITG) avβ3 which was associated with enhanced 
adhesion effect of trophoblast to the endometrium [31]. Similarly, PGE2 was also 
stated to be implicated in the adhesion of human hepatoma cell lines with increased 
secretion of ITG avβ3 [32]. Furthermore, PGE2 was shown to promote the adhesion 
of endothelial cells via cAMP and PKA dependent activation of Rac with increasing 
activity of avβ3 during tumor angiogenesis and inflammation [33]. Bai et al. 
demonstrated that PGE2 increased cell adhesion via EP1 and upregulated the 
expression of focal adhesion kinase (FAK) by activating the PKC/ c-Src and epidermal 
growth factor receptor (EGFR) signal pathway in hepatocellular carcinoma (HCC) [34].       
Like cytotrophoblast cells, cancer cells have a high proliferation rate, but 
uncontrolled growth is elicited by malignant cells. Research projects on the role of 
PGE2 in trophoblast cell proliferation are still controversial. Nicola et al. came to 
conclusion that PGE2 did not influence HTR-8/SVneo cells at physiological 
concentrations, a human trophoblast derived cell line representing extravillous 
trophoblasts proliferation [14]. However, Biondi et al. proved that the proliferation of of 
HTR-8/SVneo cells is inhibited by PGE2 inhibits the proliferation [35]. Our work was 
based on of Biondi results, which demonstrated that the selective EP2 receptor 
antagonist (PF-04418948) reduced the proliferation of HTR-8/SVneo cells in vitro[36]. 
PPARα and PPARγ agonists promoted the proliferation of trophoblasts associated with 
increased synthesis of PGE2 [37]. We speculate that the effects elicited by PGE2 in 
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increasing or inhibiting trophoblasts proliferation seem highly dependent on its 
concentration levels and which G protein receptors are activated in cells. Besides, we 
deem that more in-depth research is necessary to obtain more accurate and 
comprehensive understanding of the effects of PGE2 on trophoblasts.  
COX-2 could increase the proliferation of the ovarian cancer cell lines SKOV3 and 
OVCAR3 through PGE2 and NF-κB pathways [38-40]. Thanan et al. provided evidence 
suggesting that COX-2, which is involved in inflammation also regulates cell 
proliferation, demonstrating an increase of Oct3/4 and CD44v6 cells growth in bladder 
cancer [41]. PGE2 has been shown to promote the proliferation of cancer cells via 
multiple mechanisms. Ke et al. reported that PGE2 stimulates cellular proliferation via 
the EP4 receptor by activating the Wnt/β-catenin signaling pathway in endometrial 
cancer [42]. The Ras-MAPK kinase cascade was the main signaling pathway 
responsible for cell proliferation, and the downstream signaling Raf/MEK/ERKs and 
PI3K/AKT pathways are also involved [43]. PPARα has been associated with breast 
cancer proliferation, stimulating cyclin E expression, and mediating faster G1/S 
transition [44]. Previously published data indicated that PGE2 transactivates PPAR 
delta via PI3K-Akt signaling and promotes the development of colorectal adenomas 
[45]. These results point out that both PPARs and EPs are curial downstream 
mediators in PGE2 stimulated tumor growth. 
3.4 Influence of the PGE2 pathway in invasion and migration 
Following blastocyst adhesion, trophoblasts differentiate and acquire an invasive 
phenotype. Several pieces of evidence confirm that PGE2 facilitates trophoblast 
invasion. It has been reported that PGE2 produced from EVTs via leukemia inhibitory 
factor (LIF) and interleukin (IL)-1β stimulation promotes their invasion and migration 
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through EP1, EP2, and EP4 receptors [46]. Epithelial-mesenchymal transformation 
(EMT) is classically defined as an epithelial shift toward a more invasive and active 
mesenchymal state, modifying the adhesion molecules expressed within the cells [47]. 
EMT is involved in the process of migration and invasion, eliciting a decrease in the 
expression of the adherent junction protein E-cadherin, with concurrent elevation in the 
expression levels of vimentin, fibronectin, α-SMA, and Snail, ZEB [48]. EMT is an 
essential mechanism through which the highly plastic and dynamic germ layers and 
tissues proliferate during embryonic development and secrete exosomes to prepare 
for tissue invasion [49]; meanwhile, EMT is also involved in the process of invasion 
and metastasis of many solid tumors [50,51]. More research is needed to evaluate the 
mechanisms underlying the regulation of EMT by the COX-2-PGE2-EPs pathway. The 
COX-2-PGE2 axis was closely related to enhancing EMT in several cancer cells 
[52,53]. COX-2 elevated the level of PGE2, triggers EMT increased migration and 
invasion through matrix metalloproteinases (MMP) -2 and MMP-9 production and 
activates the NF-κB Pathway in colon cancer cells [54,55]. Additionally, the COX-2-
PGE2-EP4 axis activated the PI3K-Akt-ERK and NF-κB pathways leading to miR-655 
upregulation, and also enhances EMT in breast cancer [56]. The mechanism 
underlying the regulation of the nuclear transcription factor β-catenin by COX-2/PGE2
is responsible for the inhibition of EMT and invasion via the Gs -axin-GSK3β pathway 
in colon cancer cells [57]. Numerous papers indicated that PGE2 promotes cancer 
invasion by utilising multiple pathways, for instance the COX-2/PGE2-
PI3K/AKT/GSK3β/β-catenin pathway in gastric cancer [58]. PGE2 has been proven to 
mediate prostate cancer cell invasion and migration through activation of the 
PI3K/AKT/mTOR pathway [59]. EP4 activated cAMP-PKA-pCREB and PKA are also 
linked to the WNT/β-catenin and NOTCH pathways, inhibiting glycogen synthase 
kinase 3(GSK-3) in breast cancer [60,61].   
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PGE2 has also been shown to promote the migration of EVTs by increasing the 
intracellular concentration of calcium and activating calpain via EP1 and EP4 receptors 
via cell division control protein 42 homolog (CDC42)  and the activation of ras-related 
C3 botulinum toxin substrate 1(RAC1) and [15,46]. Nicola et al. found that the MAPK 
and ERK1/2 pathways related to PGE2 mediated stimulation of trophoblast migration 
[62]. PGE2 has been reported to induce migration by activating the phosphorylation of 
FAK and PKC/c-Src and EGFR signal pathways in hepatocellular carcinoma cells [34]. 
Woo SM et al. demonstrated that PGE2 regulates cell migration through EP2-PKA-
CREB-Scr-STAT3 signaling pathways in renal cell carcinoma [63]. Kim Jae et al. 
emitted the idea that increased expression of the COX-2 lead to stimulation of PGE2 
in the lung tumor microenvironment, which may initiate a mitogenic signaling cascade 
composed of EP4 -betaArrestin1-c-Src, hence promoting cancer cell migration [64]. 
PGE2 regulated β-catenin expression and promotes the growth and invasion of 
cholangiocarcinoma cells through the EP3-4R/Src/EGFR/PI3K/AKT/GSK-3β pathway 
[65]. Our findings were consistent with these results, supporting that PGE2 meditates 
EP3 to promote proliferation and migration with the activation of PAI-1, uPAR, and p-
ERK1/2 in cervical cancer cells [66]. Other reports revealed that in HCC cells, different 
signaling pathways including p38 MAPK, MEK/ERK, PKC and PKA are involved in the 
tumor migration induced by PGE2 [67,68]. 
3.5 Effects of the PGE2 pathway on the extracellular matrix and 
angiogenic factors 
The extracellular matrix (ECM) comprises extracellular macromolecules that maintain 
structural and biochemical support to surrounding cells, which regulates cell growth, 
migration, metastasis and differentiation [69]. Deregulation of the ECM is associated 
with the placenta's physiological development and tumorigenesis [70,71]. MMPs and 
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their inhibitors, tissue inhibitors of metalloproteinase (TIMPs), play a vital role in the 
balance of ECM remodeling, angiogenesis, embryogenesis, and cancer metastasis 
[72]. PGE2 induced trophoblast interferon secretion of MMP-1 and MMP-3 in ovine 
endometrial cells [73]. Li et al. provided evidence that PGE2 could mediate an 
increment in the secretion of MMP-9 after culturing trophoblasts with LPS in vitro [74]. 
Our previous study showed that the activation of COX-2-PGE2-Gi1-EP3-pERK1/2 
could increase the expression levels of plasminogen activator inhibitor-1 (PAI-1) and 
inhibit ECM degradation in recurrent miscarriage patients [75]. PGE2 induced EP4 
activation of the EGFR signaling pathway, which further results in degradation of the 
invadopodia-driven ECM and promotes invasion in breast cancer [76]. Furthermore, 
PGE2 can reduce dendritic cell (DC) migration by increasing TIMP-1 production in lung 
cancer.  
Both the placenta and tumors need new vascular networks to support their highly 
proliferating and invading cells. Angiogenic factors are fundamental for the 
development and endurance of endothelial cells, and to invigorate the arrangement of 
new blood vessels, vascular endothelial cell migration and capillary development. 
Vascular endothelial growth factor (VEGF), transforming growth factor-β (TGFβ), basic 
fibroblast growth factor (bFGF), tumor necrosis factor α (TNFα), and platelet-derived 
growth factor (PDGF) are well-known major regulators of angiogenesis and play a key 
role in spiral artery remodeling, as well as tumor growth. Unlike to the firmly directed 
and organized vasculature of the placenta, the veins of tumors are profoundly atypical, 
dysfunctional, and uncontrolled. Research by Matsumoto et al. demonstrated the 
association between PGE2 and VEGF expression in COX-2 deficient mice during 
implantation [77]. Through its interaction with the EP2 and EP4 receptors, PGE2 was 
shown to irritate PKA pathway activation of AP2 and Sp1 as well as acetylation of 
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histone H3 to regulate the VEGF gene’s transcriptional activity during placental and 
embryonic development [78]. The expression of COX-2 is highly correlated with TGF-
β, VEGF and the microvascular density in neoplasms [79,80]. EP2/EP4 receptors 
mediate PGE2 induction of VEGF in ovarian cancer cells [81] 
Interestingly, PGE2 is capable of inducing the pro-angiogenic chemokine called 
CXCL1, to increase tumor microvessel formation, cell invasion and cell growth in 
colorectal cancer [82]. Further evidence showed that VEGF and bFGF increase the 
production of COX-2 and PGE2 in endothelial cells [83]. We hypothesise that PGE2 
regulates VEGF and bFGF via a positive feedback loop, which further increases the 
production of PGE2 and angiogenic factors.  
3.6 Influence of the PGE2 pathway on immunosuppressive mediators 
PGE2 is generally known as a major immunosuppressive middle person hampering 
supportive of incendiary reactions in different immune cells and building up an 
immunosuppressive microenvironment. PGE2 is generally known to suppress a wide 
range of immune cells, including Th1 cells, macrophages, neutrophils, cytotoxic T cells, 
and NK cells, while promoting Th2 cells, Th17 cells, and Treg cells in the 
microenvironment [84,85]. 
The maternal-fetal interface immune-microenvironment establishes maternal 
tolerance towards the semi-allogeneic fetus. Dysfunction of these immune cells leads 
to imbalances of the maternal-fetal interface, which may contribute to pathological 
conditions of pregnancy, such as recurrent miscarriages and preeclampsia. The effects 
of PGE2 systemic alterations on immune cells were also detectable, particularly 
concerning helper T cells type 2 polarization, which was evident in the second trimester 
of pregnancy [86,87]. Mir-494 in decidual mesenchymal stem cells reduced the 
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production of PGE2, which affects macrophage polarization of the M2 type and leads 
to preeclampsia [88]. Our research team reported that the lower expression levels of 
PPARγ are associated with M2 polarization in decidual macrophages leading to 
recurrent miscarriage [89]. Nonetheless, additional efforts are needed to further assess 
the role of the PGE2 Pathway in the maternal-fetal interface and the mechanism of its 
impact on immune cells during pregnancy.    
There is a critical role played by the tumor-specific immunosuppressive 
microenvironment that leads to tumor progression and tolerance from immune 
surveillance. PGE2 can switch the Th1/ Th2 balance to promote Th2 responses, which 
tend to be dominant in neoplastic microenvironments. There were evidences that 
PGE2 has an effect on inhibiting the production of Th1 cells cytokines IL-2 and IFN-γ 
and increases the production of Th2 cytokines IL-4, IL-5 and IL-10 in cancer [90-92]. 
PGE2 induced M2 macrophage polarization via EP4 receptors promotes tumor growth 
and metastasis in lung cancer [93]. The COX-2-PGE2 axis played a central role in 
enhancing the function of myeloid-derived suppressor cells (MDSC) associated with 
immunosuppression and inhibits CD8+ T cells' ability to destroy malignant tumor cells 
[94,95]. Furthermore, Obermajer et al. elucidated that PGE2 inhibits the production of 
CXCL12, CXCR4 and blocks the recruitment of MDSC in the microenvironment of 
ovarian cancer [96]. PGE2 can promote the activation, maturation and migration of DC, 
but inhibits its ability to attract T cells to tumor cells [97,98]. The COX-2 - PGE2 axis 
decreased the expression of NK cell receptors on tumor cells [99,100]. PGE2 also 
suppressed the activity of NK cells by limiting their migration, secretion of cytotoxic 
substances, and enhanced interferon (IFN)-γ and TNF-α production by acting on EP2 
and EP4 receptors during tumor progression in breast cancer [101]. More importantly, 
PGE2 produced by tumor cells annihilates the function of NK cells by decreasing the 
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secretion of chemokine ligand (CCL) 5 and Xcl1 chemokine (C motif) ligand 1, resulting 
in cancer immune evasion [102].  PGE2 also modulated the formation and function of 
Treg cells. Barateli et al. reported that the COX-2-PGE2 axis enhances FOXP3 gene 
expression and activates Treg functions of CD4+T cells in lung cancer [103,104]. 
Additionally, Yuan et al. demonstrated that the COX-2-PGE2 axis attracted more Treg 
cells and inhibited cytotoxic T cell functions, leading to gastric cancer [105] and 
prostate cancer progression [106]. EP2 dependent signals from PGE2 have been 
proven to promote CD4+ T cells' polarization to the Th17 phenotype via the 
upregulation of IL23R in prostate cancer [107]. Finally, PGE2 induced IL-23 leads to 
Th17 cells expansion through the cAMP/PKA signaling transduction pathway in the 
tumor microenvironment [108]. 
3.7 Aims of the studies 
Despite numerous studies concerning the COX-2-PGE2-EPs axis in regulation the 
process of pregnancy and the development of cancer, a precise understanding of EPs 
receptor in several physiological and various reproductive disease should be 
conducted in more studies. So that certain EPs ligands or antagonists can be used 
clinically to improve the reproductive rates and the disease-free survival rate of cancers. 
     3.7.1 Expression of EP2 in trophoblast with recurrent miscarriage 
PGE2 involved in female reproduction, mainly in implantation, decidualization, 
blastocyst growth and development. It is necessary to understand the molecular 
regulation of EPs receptor in maternal-fetal interface, which help us more precise cure 
recurrent miscarriage. Previous research of our group showed that EP3 signaling 
contribute to remodel of extracellular matrix and produce of hormone in the maternal-
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fetal interface of recurrent miscarriage. However, the expression and function other 
EPs in the maternal-fetal interface is still unclear and need to be explore.   
    Therefore, we aimed to identify the expression level of EP1, EP2 and EP4 in 
the maternal-fetal interface with recurrent miscarriage compared to normal 
pregnancy. We then further explore the potential function of EP2 in EVTs 
relevance with recurrent miscarriage progression in vitro.
     3.72 The pathological mechanism of EP3 signaling in cervical cancer 
PGE2 through EP2 and EP4 signaling pathway affected the proliferation 
and angiogenesis of cervical cancer cell lines. Our latest publication showed 
poor prognosis in overall survival rates of cervical cancer patients due to high 
expression of EP3 in both adenocarcinoma and squamous cell. To elucidate the 
biological molecular mechanism of EP3 involved in cervical cancer and the 
downstream targets of EP3 affects the cervical cancer development.  
    Thus, we searched the relevant evidences from publicly available databases by 
bioinformaitcs analysis and desiged the experiment to evaluate the effects of EP3 in 
cervival cancer cell proliferation and migration and to figured out the associated 
mechanisms.  
3.8 Author contributions of two publications 
The whole study was designed by Udo Jeschke and Viktoria von Schönfeldt. Statistical 
analysis and compiling the manuscript was done by Lin Peng and Yao Ye after 
performing the whole experiment. Christina Kuhn did the immunohistochemistry 
staining. Heather Mullikin, Aurelia Vattai, Christian Dannecker,Sven Mahner and 
Eileen Deuster revised the manuscript. Martina Rahmeh and  Lili Lin  guided the 
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expriments. To get into agreement on the whole document, all authors scrutinized the 
whole record and agreed with the publications of the hard copy. 
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4 Publication I 
J Reprod Immunol. 2020 Oct 1;142:103210. doi: 10.1016/j.jri.2020.103210. 
Expression of trophoblast derived prostaglandin E2 receptor 2 (EP2) is reduced 
in patients with recurrent miscarriage and EP2 regulates cell proliferation and 
expression of inflammatory cytokines 
Lin Peng, Yao Ye, Mullikin Heather, LiLi Lin, Christina Kuhn, Martina Rahmeh, Sven Mahner, 
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PGE2 biology is a complex regulatory process in different cell types through stimulating 
various receptors. Our latest research found that EP3 is involved in the pathology of 
recurrent miscarriage and cervical cancer. In order to investigate other EP receptors 
in recurrent miscarriage and attempt to elucidate the molecular mechanisms by which 
the EP3 signaling pathway is implicated in the development of cervical cancer, we 
focused on the potential function of EP2 in trophoblast with recurrent miscarriage and 
the molecular regulation of EP3 signaling in cervical cancer.  
6.1 Expression and function of EP2 in trophoblast with recurrent miscarriage 
Our group did some primary studies to identify the expression level of PGE2 receptors 
(EP1, EP2, EP3 and EP4) in the maternal-fetal interface with normal pregnancy and 
recurrent miscarriage patients via immunohistochemistry. We evaluated the results 
through IRS score found that the expression of EP2 and EP4 were reduced both in 
syncytium and decidual in the recurrent miscarriage group compared with normal 
pregnancy tissue. EP2 co-expression with HLA-G predominantly exist in the cytoplasm 
especially in the cell membrane of trophoblast cells. The results clearly showed that 
EP2 antagonist (PF-04418948) inhibited the proliferation and production of substances 
(β-hCG, progesterone, IL-6, IL-8, and TNF-α) and promoted the secretion of PAI-1 in 
HTR-8/SVneo in vitro. The PGE2-EP2 axis might be an important target to gain 
knowledge for future therapy options for a better treatment of recurrent miscarriage via 
regulating the underlying pathway and the inflammatory cytokines. 
6.2 The molecular mechanism of EP3 signaling in cervical cancer 
The cervical cancer patient’s database was used to analyze the expression of EP3 
was positively correlated with PAI-1 and negatively related with uPAR expression. With 
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bioinformatics analysis we observed that EP3 is involved in ECM interaction, adherent 
junction and cell adhesion in cervical cancer. We performed a serious in vitro 
experiment which suggested that silencing of EP3 declined the proliferation and 
migration of cervical cancer cells while EP3 agonist can reverse these effects. The 
underlying mechanism thought to decrease the migration in part via inhibition of EP3 
increased the levels of PAI-1 and uPAR with the activation of pERK1/2 and P53 
transport from cytoplasmic to nuclear. The uPAR high group had a lower overall 
survival rate and advanced stages compared to uPAR low group (IRS＜2) with the 
Kaplan-analysis. Hence, the targets of EP3 and uPAR might be prognostic predictor 
and provide beneficial effects in cervical cancer patients. 
Taken together, EP2 and EP3 receptors play crucial roles in trophoblast cell 
function in the placenta and for the biology of cervical cancer. Future studies would 
focus on the role of COX-2-PGE2-EPs axis in immune cells, like T cells, macrophage, 
dendritic cells, NK cells, Treg and their cross-talk in the maternal-fetal interface with 
recurrent miscarriage. These findings might help us to obtain deeper understanding of 
the regulatory role of PGE2 in the pathological mechanism of reproductive diseases 




Die Biologie von PGE2 ist aufgrund der Stimulation verschiedener Rezeptoren 
kompliziert. Unsere neuesten Forschungsergebnisse zeigen, dass EP3 an der 
Pathologie wiederkehrender Fehlgeburten und Gebärmutterhalskrebs beteiligt ist. Um 
andere EP-Rezeptoren und den molekularpathologischen Mechanismus von EP3 bei 
der Entwicklung von Gebärmutterhalskrebs zu untersuchen, bestimmten wir die 
Expression von EP2 in Trophoblasten mit wiederkehrenden Fehlgeburten und den 
pathologischen Mechanismus der EP3-Signalübertragung bei Gebärmutterhalskrebs. 
7.1 Expression und Funktion von EP2 in Trophoblasten bei rezidivierenden 
Fehlgeburten 
Unsere Gruppe untersuchte zunächst die Expression von PGE2-Rezeptoren (EP1, 
EP2, EP3 und EP4) im Übergangsbereich zwischen Mutter und Fötus bei Patienten 
mit normaler Schwangerschaft und habituellen Aborten mittels Immunhistochemie. Die 
Expression von EP2 und EP4 im Synzytium und der Dezidua war signifikant verringert 
in der Gruppe mit wiederkehrenden Fehlgeburten im Vergleich zu der Gruppe mit 
normalen Schwangerschaften. Eine EP2-Coexpression mit HLA-G zeigte sich 
hauptsächlich im Zytoplasma insbesondere in der Zellmembran von 
Trophoblastenzellen. Die Ergebnisse zeigten deutlich, dass der EP2-Antagonist (PF-
04418948) die Proliferation und Produktion von Substanzen (β-hCG, Progesteron, IL-
6, IL-8 und TNF-α) inhibierte und förderte die Produktion von PAI-1 in HTR-8 / SVneo 
Zellen in vitro. Die PGE2-EP2-Achse könnte ein wichtiges Ziel sein, um Einblicke in 
zukünftige Therapieoptionen für ein besseres Management wiederkehrender 
Fehlgeburten durch Regulierung des zugrunde liegenden Signalwegs und 
entzündlicher Zytokine zu erhalten. 
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7.2 Der molekulare Mechanismus der EP3-Signalübertragung bei 
Gebärmutterhalskrebs 
Die bioinformatische Analyse von Patientinnen mit Gebärmutterhalskrebs ergab eine 
Assoziation von EP3 mit PAI-1, uPAR sowie mit der Prognose Außerdem wurde ein 
Zusammenhang mit ECM-Interaktionen und Zelladhäsionen gefunden. Im Folgenden 
konnten wir zeigen,dass das Silencing von EP3 die Proliferation und Migration von 
Zervixcarzinomzellen in vitro verringert, während der EP3-Agonist diese Effekte in vitro 
umkehren kann. Als zugrundeliegender Mechanismus wäre denkbar, dass das 
Silencing von EP3 die Expression von PAI-1 und uPAR erhöht. In der Folge findet 
Phosphorylierung von ERK1 / 2 und die Translokation von p53 aus dem Zytoplasma 
in den Kern statt. Daraus lässt sich die Migration von Gebärmutterhalskrebszellen 
erklären. Die hohe uPAR-Gruppe hatte eine niedrigere Gesamtüberlebensrate und 
fortgeschrittene Stadien im Vergleich zur niedrigen uPAR-Gruppe (IRS ＜ 2) mit der 
Kaplan-Analyse. Daher könnten die Ziele von EP3 und uPAR prognostische 
Prädiktoren sein und bei Patienten mit Gebärmutterhalskrebs positive Auswirkungen 
haben. 
Zusammenfassend kann festgestellt werden, dass EP2- und EP3-Rezeptoren eine 
entscheidende Rolle bei der Funktion von Trophoblastenzellen in der Plazenta und bei 
der Entwicklung von Gebärmutterhalskrebs spielen. Weitere Studien sind nötig, um 
auf die Funktion der COX-2-PGE2-EPs-Achse in Immunzellen wie Makrophagen, 
dendritischen Zellen, NK-Zellen und Tregs bei habituellen Aborten zu schließen. 
Dennoch können unsere Ergebnisse helfen, den Einfluss von PGE2 auf den 
Pathomechanismus von Fortpflanzungserkrankungen besser zu verstehen und die 
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